SH3D19

Across TCGA pan-cancer cohorts, SH3D19 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SH3D19 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SH3D19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SH3D19 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where SH3D19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.705	1.000	.001	13	view →
CCRCC	DFS	Tertile	IV	0.213	0.887	.024	10	view →
LUAD	DFS	Tertile	All	0.820	0.418	.002	6	view →
UCEC	DFS	Tertile	All	0.958	0.802	.021	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.912	.047	2	view →
PDAC	OS	Median	II,III,IV	0.745	0.963	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SH3D19–GBM (OS)

Open the GBM breakdown →